Drug reverses Alzheimer's disease deficits in mice, research confirms

An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.

The research, funded by the National Institutes of Health's National Institute on Aging and Alzheimer's Association, reviewed previously published findings on the drug bexarotene, approved by the U.S. for use in cutaneous . The Pitt Public Health researchers were able to verify that the drug does significantly improve cognitive deficits in expressing gene mutations linked to human Alzheimer's disease, but could not confirm the effect on .

"We believe these findings make a solid case for continued exploration of bexarotene as a therapeutic treatment for Alzheimer's disease," said senior author Rada Koldamova, M.D., Ph.D., associate professor in Pitt Public Health's Department of Environmental and Occupational Health.

Dr. Koldamova and her colleagues were studying mice expressing human Apolipoprotein E4 (APOE4), the only established genetic risk factor for late-onset Alzheimer's disease, or APOE3, which is known not to increase the risk for Alzheimer's disease, when a Case Western Reserve University study was published last year stating that bexarotene improved memory and rapidly cleared amyloid plaques from the brains of Alzheimer's model mice expressing mouse Apolipoprotein E (APOE). Amyloid plaques consist of fragments called amyloid beta that seem to damage neurons in the brain and are believed to cause the associated of Alzheimer's disease and, eventually, death.

Bexarotene is a compound chemically related to vitamin A that activates Retinoic X Receptors (RXR) found everywhere in the body, including neurons and other . Once activated, the receptors bind to DNA and regulate the expression of genes that control a variety of biological processes. Increased levels of APOE are one consequence of RXR activation by bexarotene. The Pitt researchers began studying similar compounds a decade ago.

"We were already set up to repeat the Case Western Reserve University study to see if we could independently arrive at the same findings," said co-author Iliya Lefterov, M.D., Ph.D., associate professor in Pitt Public Health's Department of Environmental and Occupational Health. "While we were able to verify that the mice quickly regained their lost cognitive skills and confirmed the decrease in amyloid beta peptides in the interstitial fluid that surrounds brain cells, we did not find any evidence that the drug cleared the plaques from their brains."

The Pitt researchers postulate that the drug works through a different biological process, perhaps by reducing soluble oligomers which, like the plaques, are composed of the toxic amyloid beta . However, the oligomers are composed of smaller amounts of amyloid beta and, unlike the plaques, are still able to "move."

"We did find a significant decrease in soluble oligomers," said Dr. Koldamova. "It is possible that the oligomers are more dangerous than the plaques in people with Alzheimer's disease. It also is possible that the improvement of cognitive skills in mice treated with bexarotene is unrelated to amyloid beta and the drug works through a completely different, unknown mechanism."

In the Pitt experiments, mice with the Alzheimer's gene mutations expressing human APOE3 or APOE4 were able to perform as well in cognitive tests as their non-Alzheimer's counterparts 10 days after beginning treatment with bexarotene. These tests included a spatial test using cues to find a hidden platform in a water maze and a long-term memory test of the mouse's ability to discriminate two familiar objects following introduction of a third, novel object.

Bexarotene treatment did not affect the weight or general behavior of the mice. The was equally effective in male and female mice.

More information: "Comment on 'ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models,'" by N.F. Fitz, Science, 2013.

add to favorites email to friend print save as pdf

Related Stories

Carmustine decreases amyloid beta plaques

Mar 25, 2013

Long term treatment by carmustine, a chemical relative of mustard gas and already used to treat some types of brain cancer, can decrease the amount of amyloid β and number of amyloid plaques in a mouse model of Alzheimer's ...

New perspective needed for role of major Alzheimer's gene

May 07, 2013

(Medical Xpress)—Scientists' picture of how a gene strongly linked to Alzheimer's disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found.

Recommended for you

Alzheimer amyloid clumps found in young adult brains

9 hours ago

Amyloid—an abnormal protein whose accumulation in the brain is a hallmark of Alzheimer's disease—starts accumulating inside neurons of people as young as 20, a much younger age than scientists ever imagined, ...

Alzheimer's disease linked to heart's effect on the brain

Feb 27, 2015

The prevailing medical wisdom that Alzheimer's Disease has its origins in the brain has a radical and disputed rival with shocking implications for medicine's relentless efforts to forestall disease, ageing and death, according ...

A new understanding of Alzheimer's

Feb 26, 2015

Although natural selection is often thought of as a force that determines the adaptation of replicating organisms to their environment, Harvard researchers have found that selection also occurs at the level ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.